Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Tenofovir disoproxil fumarate (tenofovir DF; Viread), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300 mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.
Lyseng-Williamson
Katherine A
KA
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Reynolds
Neil A
NA
Plosker
Greg L
GL
D000225:Adenine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001682:Biological Availability; D004311:Double-Blind Method; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate; D063065:Organophosphonates / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000068698:Tenofovir; D014018:Tissue Distribution
D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine